Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) Overview 6 Therapeutics Development 7 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Products under Development by Stage of Development 7 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Products under Development by Therapy Area 8 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Products under Development by Indication 9 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Products under Development by Companies 12 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Products under Development by Universities/Institutes 14 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Companies Involved in Therapeutics Development 21 Eli Lilly and Company 21 Neurophyxia B.V. 22 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Drug Profiles 23 2-Iminobiotin - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 IC-87201 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 NXN-188 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 NXN-462 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecule to Inhibit nNOS and iNOS for Inflammatory Pain - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecule to Inhibit nNOS and NET for Migraine and Neuropathic Pain - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecule to Inhibit nNOS and to Agonize Opioid Receptor for Pain - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecules to Activate nNOS for Diabetic Gastroparesis - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Small Molecules to Inhibit NOS for Neurodegenerative Diseases and Melanoma - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Dormant Projects 33 Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Featured News & Press Releases 34 Oct 15, 2012: Indiana University Scientists Identify New Compound That Could Prevent Post-Traumatic Stress Disorder 34 Oct 31, 2010: NeurAxon Reports NXN-188 Phase II Data Demonstrates Efficacy In Acute Migraine 34 Oct 27, 2008: NeurAxon's NXN-188 Names One Of 10 Most Promising Neuroscience Projects 35 Sep 05, 2008: NeurAxon’s NXN-188 Demonstrates Pain Relief In Migraine with Aura 36 Aug 14, 2007: NeurAxon Announces Positive Phase 1 Trial Data On NXN-188 For Migraine 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39

List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by Eli Lilly and Company, H2 2016 21 Pipeline by Neurophyxia B.V., H2 2016 22 Dormant Projects, H2 2016 33 List of Figures Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Top 10 Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 11 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Actions, H2 2016 17 Number of Products by Routes of Administration, H2 2016 18 Number of Products by Stage and Routes of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 20

Eli Lilly and Company Neurophyxia B.V.